Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 10, 2023 07:00 ET
|
Gain Therapeutics, Inc.
HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s...
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
August 07, 2023 07:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small...